{"id":"https://openalex.org/W2339878388","doi":"https://doi.org/10.1158/1535-7163.targ-15-a145","title":"Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies","display_name":"Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies","publication_year":2015,"publication_date":"2015-12-01","ids":{"openalex":"https://openalex.org/W2339878388","doi":"https://doi.org/10.1158/1535-7163.targ-15-a145","mag":"2339878388"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-15-a145","doi":"https://doi.org/10.1158/1535-7163.targ-15-a145","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-a145","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059576323","display_name":"Yusuke Ogitani","orcid":"https://orcid.org/0009-0004-2189-0644","observed_orcids":["https://orcid.org/0009-0004-2189-0644"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yusuke Ogitani","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063118578","display_name":"Junko Yamaguchi","orcid":"https://orcid.org/0000-0002-6131-0665","observed_orcids":["https://orcid.org/0000-0002-6131-0665"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Junko Yamaguchi","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015624981","display_name":"Chiaki Ishii","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Chiaki Ishii","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028262481","display_name":"Takehiro Hirai","orcid":"https://orcid.org/0000-0002-0214-1056","observed_orcids":["https://orcid.org/0000-0002-0214-1056"]},"institutions":[{"id":"https://openalex.org/I4405284387","display_name":"Daiichi Sankyo RD Novare (Japan)","ror":"https://ror.org/03ey07j79","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626","https://openalex.org/I4405284387"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takehiro Hirai","raw_affiliation_strings":["2Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I4405284387"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019192922","display_name":"Ryo Atsumi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryo Atsumi","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083108371","display_name":"Koji Morita","orcid":"https://orcid.org/0000-0001-9353-4922","observed_orcids":["https://orcid.org/0000-0001-9353-4922"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Koji Morita","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050775905","display_name":"Ichiro Hayakawa","orcid":"https://orcid.org/0000-0003-2749-9078","observed_orcids":["https://orcid.org/0000-0003-2749-9078"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ichiro Hayakawa","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054792099","display_name":"Hiroyuki Naito","orcid":"https://orcid.org/0000-0002-8080-1099","observed_orcids":["https://orcid.org/0000-0002-8080-1099"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroyuki Naito","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069087687","display_name":"Takeshi Masuda","orcid":"https://orcid.org/0000-0003-3557-0049","observed_orcids":["https://orcid.org/0000-0003-3557-0049","https://orcid.org/0000-0003-0121-4783"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takeshi Masuda","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009929659","display_name":"Takashi Nakada","orcid":"https://orcid.org/0009-0000-6846-8820","observed_orcids":["https://orcid.org/0009-0000-6846-8820"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takashi Nakada","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029467719","display_name":"Takahiro Jikoh","orcid":"https://orcid.org/0009-0000-8828-0286","observed_orcids":["https://orcid.org/0009-0000-8828-0286"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takahiro Jikoh","raw_affiliation_strings":["1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Daiichi-Sankyo Co., Ltd., Tokyo, Japan;","institution_ids":["https://openalex.org/I4210104626"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"12_Supplement_2","first_page":"A145","last_page":"A145"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9053000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0625,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.008799999952316284,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ds-8201a","display_name":"DS-8201a","score":0.9959999918937683},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.8740000128746033},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8119999766349792},{"id":"https://openalex.org/keywords/deruxtecan","display_name":"deruxtecan","score":0.8629999756813049},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8579999804496765},{"id":"https://openalex.org/keywords/her2-positive-gastric-cancer","display_name":"HER2-positive gastric cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.824999988079071},{"id":"https://openalex.org/keywords/drug-to-antibody-ratio","display_name":"drug-to-antibody ratio","score":0.8029999732971191},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.6370000243186951}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6594319343566895},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.6330452561378479},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5956825017929077},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4713430106639862},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.445349782705307},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43204233050346375},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4196126461029053},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39953431487083435},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2998631000518799},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2899709939956665},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2832927703857422},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1575189232826233},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12957310676574707},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.10847169160842896},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-15-a145","doi":"https://doi.org/10.1158/1535-7163.targ-15-a145","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-a145","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2314772071","https://openalex.org/W2737870005","https://openalex.org/W2607832876","https://openalex.org/W2741479295","https://openalex.org/W2587834458","https://openalex.org/W2738734482","https://openalex.org/W4393086484","https://openalex.org/W4220893688","https://openalex.org/W2387397851","https://openalex.org/W2621488969"],"abstract_inverted_index":{"Abstract":[0],"Antibody-drug":[1],"conjugates":[2],"(ADCs)":[3],"represent":[4],"a":[5,11,32,38,46,69,128,133,153,164,178,187,237,244,359,368,435,440,447],"promising":[6],"drug":[7,24,269],"class":[8],"which":[9,52,377],"expresses":[10],"wider":[12],"therapeutic":[13],"window":[14],"than":[15,59,192,372],"conventional":[16],"chemotherapeutic":[17],"agents":[18],"by":[19,84],"effecting":[20],"efficient":[21],"and":[22,45,56,87,99,116,183,206,248,286,308,322,374,388,392,468],"specific":[23],"delivery":[25],"to":[26,74,96,107,260,282,293],"antigen-expressing":[27],"tumor":[28,103,180,184,313,329],"cells.":[29,104],"DS-8201a":[30,81,151,176,200,235,280,327],"is":[31,53,82,100,127,138],"HER2-targeting":[33,130,361,437],"ADC":[34,67,131,438],"structurally":[35],"composed":[36],"of":[37,64,112,246,264,266,279,298,461],"humanized":[39],"anti-HER2":[40,379],"antibody,":[41],"enzymatically":[42],"cleavable":[43],"peptide-linker,":[44],"novel":[47,360,436,441],"topoisomerase":[48,443],"I":[49,271,444],"inhibitor":[50,136],"(DXd),":[51],"cell-membrane":[54],"permeable":[55],"more":[57,191,288,365],"potent":[58,289,448],"SN-38":[60],"the":[61,91,109,261,462],"active":[62],"metabolite":[63],"irinotecan.":[65],"This":[66],"achieves":[68],"high":[70,213,349,396],"drug-to-antibody-ratio":[71],"(DAR,":[72],"7":[73],"8)":[75],"with":[76,79,124,132,186,197,212,230,243,304,335,348,395,439,451],"homogeneous":[77],"conjugation":[78],"DXd.":[80],"cleaved":[83],"lysosomal":[85],"enzymes":[86],"releases":[88],"DXd":[89],"in":[90,102,114,117,122,240,331,344,367,375,393,401,407,455],"cytoplasm":[92],"after":[93],"it":[94],"binds":[95],"HER2":[97,154,214,232,337,350,397],"receptors":[98],"internalized":[101],"In":[105,146,160,195,352],"order":[106],"evaluate":[108],"pharmacological":[110],"potential":[111],"DS-8201a,":[113,217,358,434],"vitro":[115,147],"vivo":[118,161],"studies":[119,148,162,355],"were":[120],"performed":[121],"comparison":[123,196],"T-DM1.":[125],"T-DM1":[126,252,341,385,454],"commercialized":[129],"tubulin":[134,274],"polymerization":[135,275],"that":[137,150,175,357],"approved":[139],"for":[140,142],"treatment":[141],"HER2-positive":[143,165,247],"breast":[144,205,226],"cancer.":[145],"indicated":[149],"exhibited":[152],"expression-dependent":[155],"cell":[156,169,295],"growth":[157,181],"inhibitory":[158],"activity.":[159],"using":[163],"gastric":[166,207],"cancer":[167,227],"NCI-N87":[168],"line-derived":[170],"xenograft":[171,209],"(CDX)":[172],"model":[173],"suggested":[174],"induced":[177,328,342],"dose-dependent":[179],"inhibition":[182,272],"regression":[185,330,343],"single":[188],"dosing":[189],"at":[190],"1":[193],"mg/kg.":[194],"T-DM1,":[198,220,373],"1)":[199],"was":[201],"effective":[202],"against":[203,224],"T-DM1-insensitive":[204],"patient-derived":[208],"(PDX)":[210],"models":[211,229,310,334,347],"expression.":[215,233,351],"2)":[216],"but":[218],"not":[219],"demonstrated":[221],"anti-tumor":[222,449],"efficacy":[223,450],"several":[225],"PDX":[228,309],"low":[231,389],"3)":[234],"showed":[236],"complete":[238],"response":[239],"mice":[241],"inoculated":[242],"mixture":[245],"-negative":[249],"cells":[250],"while":[251],"did":[253],"not.":[254],"These":[255],"differentiations":[256],"may":[257,363],"be":[258,364,405],"due":[259,292],"different":[262],"mechanisms":[263],"action":[265],"each":[267],"conjugated":[268,299],"(topoisomerase":[270],"vs.":[273,284],"inhibition),":[276],"higher":[277,294],"DAR":[278],"(7":[281],"8":[283,312,346],"3.5),":[285],"DS-8201a's":[287],"bystander":[290],"killing":[291],"membrane":[296],"permeability":[297],"toxin.":[300],"When":[301],"taken":[302],"together":[303],"over":[305,332],"30":[306],"CDX":[307],"from":[311,453],"types":[314],"(breast,":[315],"gastric,":[316],"cholangiocarcinoma,":[317],"esophagus,":[318],"colon,":[319],"NSCLC,":[320],"pancreas,":[321],"ovary)":[323],"conducted":[324],"so":[325],"far,":[326],"20":[333],"various":[336],"expression":[338],"levels":[339],"though":[340],"only":[345],"conclusion,":[353],"these":[354],"suggest":[356],"ADC,":[362],"efficacious":[366],"broader":[369],"patient":[370],"population":[371],"tumors":[376,387,394],"current":[378],"therapies":[380],"are":[381],"ineffective,":[382],"such":[383],"as":[384],"insensitive":[386],"HER2-expressing":[390],"tumors,":[391],"heterogeneity.":[398],"The":[399],"first":[400],"human":[402],"study":[403],"will":[404],"initiated":[406],"2015":[408,471],"3Q.":[409],"Citation":[410],"Format:":[411],"Yusuke":[412],"Ogitani,":[413],"Junko":[414],"Yamaguchi,":[415],"Chiaki":[416],"Ishii,":[417],"Takehiro":[418],"Hirai,":[419],"Ryo":[420],"Atsumi,":[421],"Koji":[422],"Morita,":[423],"Ichiro":[424],"Hayakawa,":[425],"Hiroyuki":[426],"Naito,":[427],"Takeshi":[428],"Masuda,":[429],"Takashi":[430],"Nakada,":[431],"Takahiro":[432],"Jikoh.":[433],"DNA":[442],"inhibitor,":[445],"demonstrates":[446],"differentiation":[452],"preclinical":[456],"studies.":[457],"[abstract].":[458],"In:":[459],"Proceedings":[460],"AACR-NCI-EORTC":[463],"International":[464],"Conference:":[465],"Molecular":[466],"Targets":[467],"Cancer":[469,480],"Therapeutics;":[470],"Nov":[472],"5-9;":[473],"Boston,":[474],"MA.":[475],"Philadelphia":[476],"(PA):":[477],"AACR;":[478],"Mol":[479],"Ther":[481],"2015;14(12":[482],"Suppl":[483],"2):Abstract":[484],"nr":[485],"A145.":[486]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-09T09:14:12.587421","created_date":"2016-06-24T00:00:00"}